NCT05626920招募中1 期
A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Assess the effects of disulfiram on retinal sensitivity in eyes afflicted with inherited retinal degenerations
研究概览
简要总结
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years Only those with a clinical diagnosis of inherited retinal degeneration. When available, supporting genetic diagnosis form a CLIA approved lab will be further considered for inclusion.
- •Only one eye per subject should be identified as the study eye. The study eye must meet the following criteria:
- •Best corrected ETDRS visual acuity letter score ≥ 70 (i.e., 20/40 or better) within 30 days of enrollment.
- •Goldmann visual field exhibiting constriction of visual fields to 10 degrees centrally
- •Able and willing to provide informed consent
- •Willing and able to abstain from alcohol consumption for the duration of the study and the 2 weeks preceding it and 2 weeks following the study end point
- •Liver function values that fall in the normal range as specified below:
- •Alanine transaminase (ALT): less than 40 IU/L
- •Aspartate transaminase (AST): less than 40 IU/L
- •Alkaline phosphatase (ALP): less than 300 IU/L
- •Albumin (Alb): less than 50 g/L
- •Total Protein: less than 80 g/L
- •Total Bilirubin: less than 30 umol/L
排除标准
- •A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., alcohol dependence, cardiovascular disease, hepatitis.
- •Individuals with a history of diabetes mellitus
- •Individuals with a history of psychosis
- •Individuals with hypothyroidism
- •Individuals with hypersensitivity to thiuram derivatives causing rubber contact dermatitis
- •Those on anticoagulant therapy or other medications that may be affected by disulfiram.
- •An ocular condition, other than inherited retinal degeneration, is present such that, in the opinion of the investigator, visual acuity might be affected (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, non-retinal conditions such as epiretinal membrane or vitreo-macular traction, vein occlusion, uveitis or other ocular inflammatory diseases such as neovascular glaucoma, etc).
- •History of major ocular surgery within the prior 6 months or major ocular surgery anticipated within the next 6 months following randomization.
- •Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis
- •Participation in an investigational trial that involves treatment with any drug within 30 days of randomization that has not received regulatory approval at the time of study entry.
- •Note: study participants cannot receive another investigational drug while participating in this study.
- •Known allergy or hypersensitivity to any component of the study drug.
- •For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months. Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment will be used to determine when a pregnancy test is needed.
- •Participants who expect to move out of the area of the clinical center during the 8 months of the study
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo medication
干预措施: Placebo (Drug)
Disulfiram
Active Comparator
Disulfiram medication
干预措施: Disulfiram 250 mg (Drug)
结局指标
主要结局
Assess the effects of disulfiram on retinal sensitivity in eyes afflicted with inherited retinal degenerations
时间窗: Year 1
Evaluate change in contrast sensitivity measured by spatial contrast contrast sensitivity testing between disulfiram and placebo arms
次要结局
- Assess the effects of disulfiram on visual acuity in eyes afflicted with inherited retinal degenerations.(Year 1)
- Assess the effects of disulfiram on photoreceptor functionality in eyes afflicted with inherited retinal degenerations.(Year 1)
研究者
Debarshi Mustafi
Assistant Professor: Dept of Ophthamology
University of Washington
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy SubjectsEffect of Orally Administrated Moxaverine on Ocular Blood FlowNCT01629680Medical University of Vienna16
已完成
2 期
Effects of Moxaverine and Placebo on Ocular Blood FlowRegional Blood FlowOcular PhysiologyRetinaNCT00709423Medical University of Vienna16
Unknown
不适用
Causes of Visual Loss in Retinal DiseaseScleritisUveitisNCT01613963Royal Surrey County Hospital NHS Foundation Trust2,000
已完成
不适用
Exploratory Study on the Effect of SAT-001 on Choroidal Thickness in Pediatric Myopia PatientsMyopiaNCT06729723S-Alpha Therapeutics, Inc.20
已完成
4 期
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) PatientsParkinson DiseaseNCT00144300Boehringer Ingelheim246